Cargando…
Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
We examined whether access to US-approved orphan drugs in Canada has changed between 1997 (when Canada chose not to adopt an orphan drug policy) and 2012 (when Canada reversed its policy decision). Specifically, we looked at two dimensions of access to US-approved orphan drugs in Canada: (1) regulat...
Autores principales: | Herder, Matthew, Krahn, Timothy Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Longwoods Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872554/ https://www.ncbi.nlm.nih.gov/pubmed/27232238 |
Ejemplares similares
-
Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada
por: Herder, Matthew
Publicado: (2016) -
Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
por: Gibson, Shannon, et al.
Publicado: (2015) -
Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010) -
Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019) -
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)